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Abstract Preterm delivery is associated with neurodevelopmental impairment caused by 
environmental and genetic factors. Dysfunction of the excitatory amino acid transporter 2 (EAAT2) 
and the resultant impaired glutamate uptake can lead to neurological disorders.	 In this study we 
investigated the role of single nucleotide polymorphisms (SNPs; g.-200C>A and g.-181A>C) in the 
EAAT2 promoter in susceptibility to brain injury and neurodisability in very preterm infants born at or 
before 32 weeks gestation. DNA isolated from newborns’ dried blood spots were used for 
pyrosequencing to detect both SNPs. Association between EAAT2 genotypes and cerebral palsy, 
cystic periventricular leukomalacia and a low developmental score was then assessed. The two 
SNPs were concordant in 89.4% of infants resulting in three common genotypes all carrying two C 
and two A alleles in different combinations. However, in 10.6% of cases non-concordance was found, 
generating six additional rare genotypes. The A alleles at both loci appeared to be detrimental and 
consequently, the risk of developing cerebral palsy increased four- and six-fold for each additional 
detrimental allele at -200bp and -181bp, respectively. The two SNPs altered the regulation of the 
EAAT2 promoter activity and glutamate homeostasis. This study highlights the significance of 
glutamate in the pathogenesis of preterm brain injury and subsequent development of cerebral palsy 
and neurodevelopmental disabilities. Furthermore, the described EAAT2 SNPs may be an early 
biomarker of vulnerability to neurodisability and may aid the development of targeted treatment 
strategies. 
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Introduction 
 
Progress in perinatal care over the last three decades has led to greater survival rates in infants born 
prematurely [1, 2]. The incidence of premature birth in developed countries varies from 7.6-12% of 
all births [3]. While 90% of very preterm infants (below 32 weeks gestation) now survive beyond the 
postpartum period, ~35% have neurodisabilities [4]. These disabilities include cerebral palsy, 
cognitive- and behavioural problems [5]. The estimated cost of preterm birth throughout childhood 
in England and Wales with a birth rate of 700,000/year is around £3 billion per annum [6]. 
Susceptibility of a preterm infant to neurodisability is difficult to predict, shows considerable variation 
between individuals [7] and is likely to be modulated by genetic factors [8]. Better diagnostic 
approaches for the early identification of infants with higher risk of neurodisability are important to 
facilitate the development and application of appropriate treatment strategies. 
Much of the neurodisability seen in very preterm infants is caused by white matter injury, known 
as periventricular leukomalacia (PVL) and the subsequent disruption of normal neural connectivity 
[9]. While the pathogenesis of PVL remains to be established, in vitro and in vivo animal studies 
have identified important roles for oxidative stress, cytokine-mediated injury and glutamate-induced 
excitotoxicity [10, 11]. Following hypoxia-ischaemia, the excitatory neurotransmitter glutamate is 
released into the extracellular space, causing over-activation of ionotropic glutamate receptors 
present in pre-myelinating oligodendrocytes [12], which induces their excitotoxic cell death and 
subsequent white matter lesions [10]. 
In the brain, neuronal and glial excitatory amino acid transporters (EAATs) play a key role in 
maintaining extracellular glutamate below neurotoxic levels. The activity of the predominantly 
astroglial high affinity glutamate transporter EAAT2 (also known as solute carrier family 1 member 2 
- SLC1A2 or the rodent ortholog glutamate transporter 1 - GLT-1) is responsible for 90% of total 
glutamate uptake [13, 14]. Furthermore, EAAT2 has been implicated in the pathology of cerebral 
ischemia [15]. While ischaemic brain injury was exacerbated in transgenic mice lacking the EAAT2 
protein in the brain [16], up-regulation of EAAT2 provides neuroprotection [15]. EAAT2 is widely 
expressed in the white matter of the developing human brain [17] and up-regulated in reactive 
astrocytes in post mortem brain tissue of preterm infants with PVL, which may indicate a response 
to either hypoxic-ischemic injury or inflammation [18]. Collectively these findings suggest that 
dysregulated EAAT2 activity may contribute to white matter damage. 
A functional single nucleotide polymorphism (SNP) in the promoter region of the EAAT2 gene has 
been associated with higher serum glutamate levels in adults and consequently a worse neurological 
outcome after stroke [19] and also with relapsing multiple sclerosis [20]. These studies raised the 
intriguing possibility that similar genetic differences may enhance predisposition to 
neurodevelopmental impairment after preterm birth. The aim of this study was to establish the role 
of two closely linked functional SNPs in the EAAT2 gene promoter [19, 21] in susceptibility to brain 
injury and neurodisability in very preterm infants. 
 
 
Materials and Methods 
 
Patient selection 
 
The risk of CP in infants born <33 weeks of gestation is 30 times higher than among those born at 
term [22]. Therefore, our study included infants born at this vulnerable period. Newborns’ dried blood 
spots and clinical data were obtained from all infants born ≤ 32 weeks of gestation and survived to 
discharge in the South West of England recruited to the Avon Premature Infant Project (APIP; 1990-
1993, n=329 [23]) or received care within the neonatal unit of Gloucestershire Royal Hospital (2002-
2008; n=127); Southmead Hospital, North Bristol NHS Trust (2005-2010; n=169) or St Michael’s 
Hospital, University Hospitals Bristol NHS Trust (2002-2008; n=196). Infants with major congenital 
anomalies of the central nervous system and genetic syndromes that may cause 
neurodevelopmental impairment or cerebral palsy were excluded. The archived blood spots were 
fully anonymised according to the Human Tissue Act and Medical Research Council (UK) Guidance 
and used for research without individual informed consent as permitted by the UK newborn screening 
programme Code of Practice for the retention and Storage of Residual Spots (April 2005, ISBN 
0955013801). From the total (n=821 infants) 208 blood spots were not traceable, 1 was excluded 
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with a chromosomal abnormality, 10 DNA samples failed all pyrosequencing assays, and 61 infants 
had no outcome data; leaving a total of 541 infants for the analyses (Table 1).  
 
Sample collection and DNA isolation 
 
Blood was collected from heel prick blood sampling on blood spot screening cards prepared routinely 
within 5-8 days of birth as part of the UK Newborn Screening Programme 
[http://newbornbloodspot.screening.nhs.uk]. DNA was isolated as described previously [24]. 
 
Generation of biotinylated PCR products for pyrosequencing 
 
Two sequence-specific primers (EAAT2PyroF-BIO and EAAT2PyroR; Table 2) were designed to 
amplify a 166bp region of the EAAT2 promoter which included the two SNPs rs111885243:C>A or 
g.-200C>A (at positions -200 bp) and rs4354668:a>c or g.-181A>C (at position -181 bp) using the 
software provided by Qiagen Pyrosequencing. The 5’ end of the forward primer was modified with 
biotin. PCR reactions contained 4-6 ng of genomic DNA, 1X PCR buffer (100 mM Tris-HCl, 500 mM 
KCl pH 8.3), 1.5 mM MgCl2, 200 µM of each dNTP, 100 pmol of each oligonucleotide and 1 unit of 
high fidelity Taq polymerase (FastStart High Fidelity Taq Polymerase, Roche Diagnostics Limited, 
West Sussex, UK) per reaction. Amplification was performed as follows: 95°C for 5 min; 50 cycles 
of 94°C for 30 s, 60°C for 30 s; 72°C for 30 s; and final extension 72°C for 10 min. Two additional 
SNPs; rs116392274 in EAAT2 and rs1835740 [21], which is involved in glutamate homeostasis, 
were also analysed in the cohort and data are shown as Supplementary materials.  
 
Pyrosequencing and Sanger sequencing 
 
All steps were carried out as previously described (Table 2) [21, 24]. Genotypes of randomly selected 
samples (n=51) from pyrosequencing were confirmed by Sanger sequencing (using ABI 3730xl 96 
capillary DNA Analyzers) at Eurofins MWG Operon (Ebesberg, Germany). 
 
Primary astrocyte cultures and preparation of the EAAT2 promoter constructs 
 
Primary rat astrocytes were separated from mixed glial cultures of embryonic (E20) Sprague-Dawley 
rat brains (Harlan, UK) using the previously described selective detachment (shaking) method [25]. 
Following separation at day 10 in vitro, astrocytes were maintained in T75 cell culture flasks (Corning 
Incorporated, New York, USA) at 37°C in a humidified 5% CO2: 95% air atmosphere. Cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (Sigma Aldrich, Missouri, USA) containing 4.5 g/L 
glucose, 29 mM sodium bicarbonate, 50 U/ml penicillin, 50 μg/ml streptomycin (Sigma Aldrich, 
Missouri, USA) and 10% (v/v) foetal bovine serum (Life Technologies Ltd., Paisley, UK). Glial 
fibrillary acidic protein immuno-labelling and trypan blue staining [26, 27] were used to confirm the 
purity and viability of the astrocyte cultures. Previously described oligonucleotides were used to 
amplify a 773bp fragment of the EAAT2 promoter [19]. Genomic DNA of genotype 1 and genotype 
3 was amplified in 25 µl reactions containing 2 µl genomic DNA, 1X High Fidelity PCR buffer (100 
mM Tris-HCl, 500 mM KCl pH 8.3), 1.5 mM MgCl2, 200 µM of each dNTP, 100 pmol of each 
oligonucleotide 1 unit of high fidelity Taq polymerase (FastStart High Fidelity Taq Polymerase, Roche 
Diagnostics Limited, West Sussex, UK). Amplification was performed as follows: 1 cycle at 95°C for 
5 min; 35 cycles of 94°C for 30 s, 65°C for 30 s 72°C for 1 min; and final extension at 72°C for 10 
min. Following enzyme digestion and fragment purification, the promoter fragment was inserted 
upstream of the firefly luciferase reporter in the pGL3-basic luciferase reporter vector. 
 
Transfection of astrocytes and luciferase reporter gene assay 
 
Cells were seeded at a density of 1 x 105 per well in 1 ml of complete growth medium in a 12 well 
plate (Corning Incorporated, New York, USA) 24 h prior to transfection. At >80% confluency the cells 
were transfected using 1 µg of EAAT2 promoter construct (EAAT2PrWT -200bp C/C -181bp A/A; or 
EAAT2PrMT -200bp A/A -181bp C/C) and 10 µl of TransIT®-Neural Transfection Reagent (Mirus 
Bio, Madison, WI 5371, USA) in Opti-MEM® I Reduced Serum Media (Life Technologies Ltd., 
Paisley, UK). 100ng of pRL-thymidine kinase plasmid (Promega, Wisconsin, USA) containing the 
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Renilla luciferase gene was co-transfected with each construct and used as an internal control. 48 h 
post transfection, the cells were washed and harvested for the promoter activity assay. All 
transfections were carried out in triplicates and all experiments were repeated three times. EAAT2 
promoter activity was determined using the Dual-Luciferase Reporter (DLR) Assay System 
(Promega, Wisconsin, USA) following the manufacturer’s guidelines. 
 
Patient outcome measures 
 
The primary outcome measure was the diagnosis of cerebral palsy. Cerebral palsy was diagnosed 
when a disorder of movement and posture causing activity limitation were present at clinical 
examination performed at 2 years of age [28]. The secondary outcome measures were (i) cystic PVL 
diagnosed on a cerebral ultrasound scan during the neonatal stay and (ii) a low developmental score 
using standardised developmental assessment tools at 2 years of age. Cerebral ultrasound scans 
were performed as part of routine clinical monitoring by the clinicians in all four groups of infants. 
Cystic PVL was diagnosed as standard [29] (i.e. when any cystic changes were visible in the 
periventricular white matter on ultrasound).  
Standardised developmental assessment data was available for three of the four infant groups 
(Table 3). The Griffith Mental Developmental Scale [30] was used for the APIP and the 
Gloucestershire Royal Hospital group, while the Bayley Scales of Infant Development (BSID) score 
(initially version II to 2006, version III after 2006 to-date) [31, 32] for the St Michael’s Hospital group. 
BSID-II is divided into two subscales (i) cognitive (Mental Developmental Index; MDI) and (ii) motor 
(Psychomotor Developmental Index; PDI). The updated BSID-III has three subscales; cognitive, 
language and motor PDI. Infants falling in the lowest 10th centile for either the main score (Griffith) 
or any of the sub-scales (BSID) in each infant group were defined a priori as having a low 
developmental score. Birth weight, gestational age at birth and physiological condition during the 
first 5 min after birth (Apgar scores at 1 and 5 min) were considered a-priori possible confounders. 
 
Statistical analysis 
 
Initially the perinatal/intra-partum characteristics (gestation, birth weight, gender, multiple births, 
ethnicity and Apgar score) of the population were assessed, split by their genotype. Then univariable 
associations were assessed, between the two EAAT2 genotypes and the primary and secondary 
outcome measures (see previous section). Due to the data coming from multiple infant groups with 
different developmental tools, multi-level logistic regression models were derived using the Stata 10 
(Stata Corp, TX, USA) “xtlogit” command, to investigate the association of the odds of each 
additional polymorphic allele and the outcome measures. Adjustment for possible confounders was 
performed by adding the perinatal/intrapartum variables described above to the logistic regression 
models as continuous variables. Two sensitivity analyses were performed (i) the analysis was 
repeated using single-level (rather than multi-level) modelling; and (ii) the missing covariates were 
imputed to allow the adjusted analysis to contain the same number of individuals as the unadjusted. 
Genotypes or outcome data was not imputed. Imputation was performed using multiple imputation 
with chained equations [33]. Details of imputation technique are available on request. All analyses 
were conducted with Stata 10 (Stata Corp, TX, USA) or Excel (Microsoft Corp, WA, US). All data are 
presented as odds ratio (OR) (95% confidence interval (CI)), mean (SD), or number (percent (%)). 
 
 
Results 
 
Simultaneous pyrosequencing of two SNPs in the EAAT2 promoter 
 
A functional SNP was reported previously in the EAAT2 promoter at -181bp (rs4354668) [19]. Our 
detailed investigation of the EAAT2 promoter using Sanger sequencing revealed another SNP, 19bp 
upstream of rs4354668, at position -200bp (rs111885243) [21]. These two SNPs cannot be 
distinguished by single strand conformational polymorphism used in the previous study [19], 
therefore a pyrosequencing assay was developed (Fig. 1). All traceable blood spots were analysed 
(n=613) by pyrosequencing and 521 produced clear pyrograms. Ten percent of these samples 
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(n=51) were sequenced and the concordance with pyrosequencing was 100%. In total, 471 of the 
infants had clinical outcome available for the analysis of rs4354668 and rs4354668.  
 
Distribution of different alleles in the study population 
 
Nine genotype combinations were identified (Table 4 and Fig. 1). In 419 samples (88.9%) the two 
SNPs were in Linkage Disequilibrium (p<0.001). Linkage Disequilibrium was not complete and hence 
the nine different genotypes (Table 4). The majority of alleles demonstrated high levels of 
concordance, such that if the -200 locus was homozygous (C/C or A/A) the -181 locus was also 
homozygous (A/A or C/C) and if -200 locus was heterozygous the -181 locus was heterozygous as 
well (Table 4; Genotypes 1-3). In the rarer genotypes (11.0% of the cases, Table 4; Genotypes 4-9) 
the alleles were non-concordant between the two polymorphic loci. We investigated rs116392274 
(g.-168C > T) in the EAAT2 promoter in the cohort but apart from one infant, who was a heterozygote, 
all others carried C/C alleles. Allele distribution of rs1835740 is shown in Supplementary materials.   
 
EAAT2 promoter activity 
 
To analyse the functional effects of the -200 C>A; -181A>C SNPs on transcriptional activity in vitro, 
genotype 1 (-200 C/C; -181 A/A) or genotype 3 (-200 A/A; -181 C/C) reporter constructs were 
transiently transfected into primary astrocytes, together with the pRL-TK vector as an internal control 
that constitutively expresses the Renilla luciferase. The genotype 1 promoter construct displayed 
between 4-4.7-fold greater activity compared with the genotype 3 construct (p<0.0015; Fig. 2). 
Several attempts were made to measure the promoter activity of genotypes 5 and 8 using initially 
the three clinical samples that carried these genotypes (Table 4). These blood samples were 15-20 
years old and the isolated gDNA and the resulting PCR products were of insufficient quality [24] for 
successful ligation to produce the required promoter constructs. In an alternative approach, we 
attempted to generate these variants using site directed mutagenesis of genotypes 1 and 3. 
However, due to the very high GC content of the promoter amplicon (over 70%; [34]) no correct 
mutants were obtained. 
 
Characteristics of the cohort 
 
The intrapartum/perinatal characteristics of the eligible infants split by groups or genotypes are 
shown in Tables 1 and 5. Importantly, the patient outcome measures (e.g.: the rate of cerebral palsy 
(p=0.284), cystic PVL (p=0.553) and low developmental scores (p=0.084)) did not differ between the 
four groups investigated (Table 1) and thus were combined for subsequent analysis. An association 
between ethnicity and genotype was observed (p<0.001) when the whole cohort was investigated 
(Table 5). To better understand the nature of the association between ethnicity and the two SNPs, 
the cohort was investigated in more details. While there was no difference in the individual 
frequencies at the two SNPs by ethnicity (-181, p=0.206 and -200, p=0.854), white infants were more 
likely to show the concordance discussed above than non-white infants (94.6% vs. 76.1%, p<0.001). 
Data on ethnicity was available for three of the four infant groups (Table 1) and within this population 
of preterm infants there was strong evidence of deviation from the Hardy-Weinberg equilibrium 
(p<0.001). 
 
Outcome measures 
 
In the univariable analyses (in which associations were assessed between each of the EAAT2 SNP 
and the primary and secondary outcome measures independently), there was no clear evidence for 
an association between different alleles with cerebral palsy, cystic PVL or a low developmental score 
(Table 6). However, when adding both polymorphisms into the multivariable analysis, the presence 
of A alleles at -181bp and -200bp appeared to increase the likelihood of a low developmental score 
with Odds Ratios (OR) of 4.56(1.53-13.60) and 3.73(1.29-10.80), respectively (Table 7; Unadjusted 
(1)). This association persisted in the analysis adjusted for gestation, birth weight, gender and 
physiological condition at birth (Table 7; Adjusted (2)). In contrast, there was less evidence for any 
association between either allele and cerebral palsy or cystic PVL. Due to the association seen with 
ethnicity (Table 5), this covariate was added to the model in a final adjusted analysis (Table 7; 
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Adjusted (3)). In this final model the association with cerebral palsy strengthened with each additional 
A allele (Locus -200bp OR 4.34 (1.12-16.77) and Locus -181bp OR 6.64(1.76-25.07)), although there 
was less evidence that the polymorphism at locus -200bp remained associated with an increased 
risk of a low developmental score (OR 2.84 (0.71-11.44)). Repeating the analysis using a model 
where the missing covariate data was imputed the results were compatible with the main analysis.	
The single infant who was a heterozygote for rs116392274 had no CP or a low developmental score. 
Similarly, no association was observed between rs1835740 and CP or a low developmental score 
(Supplementary Materials).  
 
 
Discussion 
 
SNPs in EAAT2 promoter are associated with neurodevelopmental impairment after preterm 
birth 
 
To our knowledge, this is the first study that demonstrates association between genetic variants of 
EAAT2 involved in maintaining glutamate homeostasis and neurodevelopmental impairment in very 
preterm infants. We identified that SNP g.-200C>A in the EAAT2 promoter is strongly linked to the 
previously described functional SNP g.-181A>C [19], which has not been reported in earlier studies 
[19, 20, 35]. The A alleles at both loci appear to increase the risk of cerebral palsy and low 
developmental scores (Table 7). In the common concordant inheritance pattern (Table 4, genotypes 
1-3) the protective C and detrimental A alleles are usually inherited together whereas in the rare non-
concordant genotypes only detrimental alleles (Tables 4 and 8, genotypes 4/5/7) or just protective 
alleles (Tables 4 and 8, genotypes 6/8/9) were found at both loci. This concordance was more likely 
with white ethnicity. Due to the strong linkage between the two SNPs it was appropriate to enter both 
into the multi-level regression analysis to assess the impact of increasing detrimental A alleles.  In 
the multi-level regression analysis (Table 7) adjustment for gestation, birth weight, gender, multiple 
births and Apgar scores made no significant difference to the odds of any of the outcome measures.  
However, the addition of ethnicity into the regression analysis strengthened the effect seen on 
cerebral palsy at both loci. In addition, the odds of a low developmental score were also significantly 
increased with each A allele at -181bp. To put this in context, for each additional A allele at -181 or 
-200 the odds of cerebral palsy increased by about four and six-fold and the odds of a low 
developmental score increased four-fold. The prevalence of cerebral palsy or a low developmental 
score was as high as 28 and 44% for Genotypes 7 and 4 with three detrimental alleles, respectively 
(Table 8). In contrast, no association was observed	between rs116392274 or rs1835740 and CP or 
a low development score in the cohort indicating that these SNPs are unlikely to play important roles 
in the injury of the developing brain (Supplementary materials). 
 
Regulation of EAAT2 promoter activity 
 
These two SNPs significantly affect EAAT2 promoter activity in vitro. The promoter fragment -
742/+31 [19] containing -200A/A -181C/C sequence (genotype 3) showed a 70-80% reduction in 
basal EAAT2 promoter activity compared to -200C/C -181A/A (genotype 1; Fig. 2). This is a larger 
impact than the previously reported ~30% reduction [19], however in that study the SNP at position 
-200bp was not identified and it is not clear which nucleotide was present in their promoter construct. 
The change from A to C at -181bp abolishes the binding site for transcription factor AP-2 (activating 
enhancer binding protein 2) and creates a site for GC-binding factor 2 (GCF2) which represses 
EAAT2 expression (Fig. 3; [19]). Reduced EAAT2 expression alters extracellular glutamate levels 
[13]. Despite the large difference in EAAT2 promoter activity between genotypes 3 and 1, there was 
no clear association with low developmental score or cerebral palsy in any of the main three 
genotypes (Table 8; genotypes 1-3). Similar observations were made in patients with multiple 
sclerosis [20] and migraine [36] where the allele and genotype frequencies for the EAAT2 promoter 
polymorphism were similar in patients and controls. However, the polymorphism at -181bp was 
associated with higher plasma glutamate concentrations during relapsing multiple sclerosis [20]. 
Gene expression in the nervous system is not only controlled by the transcriptional machinery, 
but it is also subject to modulation by epigenetic mechanisms such as DNA methylation [36, 37]. 
Dynamic DNA methylation is observed during brain development [38, 39] and levels of DNA 
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methylation are increased upon ischemic injury [40]. Recent studies revealed that the basal 
transcriptional activity of the EAAT2 gene is controlled by DNA methylation of cytosine residues in 
the region of -1010 to -1bp of the EAAT2 promoter [41, 42]. Hypermethylation of the EAAT2 promoter 
is involved in repression of EAAT2 activation [42]. Furthermore, a recent study revealed significant 
differences in the methylation of ten genes involved in neuronal and glial signalling, 
neurotransmission, apoptosis and cellular energetics between preterm and term infants [43]. 
Importantly, amongst these genes was EAAT2, which promoter was differentially methylated at 
multiple CpG sites. Additionally, significant variation of EAAT2 promoter activity was observed in 
different brain regions and even between neighbouring cells [44]. These findings indicate that EAAT2 
promoter is dynamically regulated under physiological conditions. In genotypes 4/5/7 the C-alleles 
at both -200bp and -181bp are replaced partially or fully by A-alleles (Table 8), which might interfere 
with the normal methylation process and the binding of GCF2 transcription factor to the EAAT2 
promoter [19] (Fig. 3).  
 
Regulation of glutamate level by EAAT2 in the developing brain 
 
One major pathology associated with cerebral palsy is PVL [10]. Oligodendrocyte cell death is 
particularly prominent following hypoxia-ischemia, which leads to hypomyelination [9]. Although the 
causes of PVL are not completely understood, cerebral ischemia is likely to play an important role 
[9, 10] implicating glutamate excitotoxicity, and excessive activation of ionotropic glutamate 
receptors [12]. The regulation of glutamate concentration in the extracellular space by EAAT2 is 
therefore essential for normal synaptic function [13] as well as neuronal survival by preventing 
excitotoxicity [16]. However, when there is a dissipation of electrochemical gradients across the 
plasma membrane as occurs during hypoxia-ischemia, EAAT2 operates in reverse to release 
glutamate, thereby promoting excitotoxicity [45]. In a rat model, glutamate was reduced in 
oligodendrocytes and axons following hypoxia-ischemia suggesting that these are the main sources 
of glutamate in developing white matter [46]. Furthermore, EAAT2 deficient mice are more vulnerable 
to neuronal loss in the hippocampus following a short episode of ischemia, while the wild-type mice 
are more vulnerable to neuronal death following prolonged ischaemia [47]. These findings suggest 
that in prolonged ischaemia EAAT2 becomes the major contributor to abnormal concentrations of 
extracellular glutamate. EAAT2 expression is limited primarily to oligodendrocytes early in 
development and is increased during the period when the premature infant is most vulnerable to 
PVL [17]. Furthermore, EAAT2 protein level was found to increase substantially in some cases of 
PVL compared to age-related controls [18]. Similarly, a recent study showed that EAAT2 is 
selectively expressed in cortical layer V neurons that are damaged in premature infants with PVL 
[48] and hypothesized that the reversal of glutamate transport by EAAT2 together with 
hyperactivation of ionotropic glutamate receptors contribute to excess ambient glutamate and 
consequently cell death specifically in these neurons [49]. Taking together, these data indicate that 
in the developing white matter it is advantageous to have the ability to dynamically down-regulate 
EAAT2 expression during ischaemia. Our genetic data supports this hypothesis; C-alleles at -200bp 
and/or -181bp allow for dynamic alteration of EAAT2 expression via methylation and by the binding 
of GCF2 transcription factor (Fig. 3). In contrast, in infants who carry mainly A alleles, regulation of 
EAAT2 via these mechanisms is impaired, which increases ischaemic vulnerability and subsequent 
impaired neurodevelopment and cerebral palsy. 
 
Study design benefits and limitations 
 
This study included all infants of 32 weeks gestation or less, including multiples who survived the 
first 5-8 days of life. Consequently, preterm infants with severe brain injury due to hypoxia-ischaemia 
or intraventricular haemorrhage, who often die in the first few days of life, were not included which 
may explain the deviation from the Hardy-Weinberg equilibrium. Participants originated from four 
different infant groups/neonatal centres in the South West of England and included all ethnic groups 
and therefore the findings are applicable to the whole UK population of preterm infants. However, 
due to the retrospective design of the study not all bloodspots could be traced from the complete 
population. The use of different neurodevelopmental assessment tools for the different groups 
precluded the use of raw cognitive or motor scores as continuous variables. The pragmatic solution 
was to classify those in the lowest 10th percentile of each group for each subscale/score as having 
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a low developmental score. The lowest 10th percentile for each score translated as two standard 
deviations below the normal population mean, which is widely accepted as the cut-off for 
moderate/severe developmental impairment when using a single developmental assessment tool in 
clinical studies [50]. Cystic PVL was diagnosed on routine clinically directed cerebral ultrasound and 
white matter injury was reported and coded if it was severe and cystic in nature. We included an 
extra group with cystic PVL data (Table 1; Southmead Hospital) but despite increasing the power of 
the analysis, there was no evidence for an association between the SNPs tested and the measurable 
ultrasound changes. The overall proportion of cystic PVL in this work was 6.7%, which is not 
statistically different from the population rate in the UK Vermont Oxford dataset at the time (4.8%; 
p=0.117). These data suggest that milder (non-cystic) white matter injury may not have been 
detected on clinical cerebral ultrasound in these groups and consequently an association with 
EAAT2 genotype and white matter damage was not found. Magnetic Resonance imaging, which is 
more sensitive in detecting milder grades of white matter injury [51] is not used routinely in the UK 
to screen the preterm brain. These neuroimaging approaches performed in the first weeks of life are 
imprecise surrogate markers of neurological function. Therefore, structured functional neurological 
assessment at 2 years for cerebral palsy and neurodevelopmental impairment (used in this study) is 
considered to be the gold standard measure of neurological outcome in preterm infants [52]. 
 
Conclusions 
 
In this study we have found that g.-200C>A and 181A>C SNPs are associated with both clinical 
neurodevelopmental outcomes and measurable in vitro effects on glutamate homeostasis. These 
findings indicate that glutamate is likely to be involved in the pathogenesis of brain injury and 
subsequent development of cerebral palsy and neurodevelopmental impairments in the human 
infant. It is plausible that g.-200C>A SNP may also have a major effect on the development of 
neurological diseases in the adult population as this SNP is so closely linked to the g.-181A>C SNP, 
which was reported to affect neurological function after adult stroke [19], multiple sclerosis [20] and 
in schizophrenia [35]. The described EAAT2 SNPs may have utility as a viable early biomarker of 
cerebral palsy and long-term neurodisability in high-risk preterm infants. These results warrant a 
prospective study with complete recruitment (including non-survivors) to confirm the utility as early 
biomarker of neurological outcome. Our results also validate the notion that glutamate plays a pivotal 
role in preterm brain injury and opens the debate around exploration of glutamate uptake 
manipulation as potential pharmacological intervention for the prevention of preterm brain injury in 
infants with this genetic vulnerability. Better understanding of the dynamic transcriptional regulation 
of EAAT2 during the perinatal period may be key to the future development of effective clinical 
interventions. 
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Figure legends 
 
 
Fig. 1. Pyrograms of the EAAT2 promoter SNPs. The position of the SNPs is highlighted in yellow 
boxes, the x-axis of each pyrogram indicates the order of reagent addition (E - enzyme, S - substrate 
and nucleotide A, G, T or C); the y-axis shows the light intensity generated. The numbering of 
pyrograms corresponds to the genotype numbers in Table 2. Due to the high GC content of the 
target sequence and the four C repeats before the SNP at position -181bp, the pyrosequencing was 
carried out on the reverse strand. Thus, note that the sequence is in reverse orientation. 
 
Fig. 2. Promoter activity of EAAT2. Astrocytes were transiently transfected with sequences 
corresponding to genotype 1 (-200 C/C; -181 A/A) and 3 (-200 A/A; -181 C/C) reporter constructs. 
Firefly and R. reniformis luciferase activities were measured as detailed in the Methods and the 
relative firefly/Renilla luciferase values are shown. Bars represent relative luciferase values from 
three independent experiments with standard deviation. 
 
Fig. 3. Proposed model of the SNPs impact on EAAT2 gene regulation. (A) EAAT2 promoter 
contains a consensus binding site for transcription factor activating enhancer binding protein 2 (AP-
2), which is an activator of transcription in the developing brain [53]. (B) Nucleotide change from A 
to C at -181bp abolishes this AP-2 consensus sequence and creates a binding site for transcription 
factor GC-binding factor 2 (GCF2) which represses EAAT2 gene expression [19]. (C, D) EAAT2 
promoter is not only controlled by the transcriptional machinery, but is also subject to modulation by 
epigenetic mechanism such as DNA methylation at CpG dinucleotides that inhibits gene expression 
[38, 39, 41, 42]. DNA methylation is reversible and subject to dynamic regulation throughout 
embryogenesis. Nucleotide changes from C to A might interfere with the normal DNA methylation 
process of EAAT2 at both -200bp and -181bp, affecting gene expression. The ability to down 
regulate EAAT2 in the developing brain seems beneficial since infants with three C alleles have 
better outcomes than those with only one. 
 
 
Tables 
 
Table 1. Birth-related information and neurodevelopmental outcomes (n=541). Values 
are numbers with % or means ± standard deviation, as appropriate. All measures were 
analysed independently so denominator may vary. 
 
Measure 
Avon 
Premature 
Infant Project 
(APIP; n=228) 
Gloucestershire 
Royal Hospital 
(n=90) 
Southmead 
Hospital  
(n=81) 
St Michael’s 
Hospital 
(n=142) 
Gestational age 
(week) 
29.9 (± 2.0) 27.8 (± 2.2) 26.8 (± 1.8) 27.4 (± 1.7) 
Birth weight (g) 1,435 (± 384) 1,130 (± 347) 916 (± 278) 992 (± 404) 
Male 131 (57.5%) 44 (49.4%) 42 (52.5%) 69 (50.4%) 
Multiple Birth 48 (21.1%) 27 (30.0%) 29 (36.3%) 35 (25.6%) 
White ethnicity 209 (92.1%) 80 (90.9%) - 44 (81.5%) 
Apgar score 
   1 minute 6.3 (± 2.2) 6.2 (± 2.1) 5.7 (± 2.1) 6.3 (± 2.1) 
   5 minute 8.5 (± 1.6) 8.4 (± 1.5) 7.6 (± 2.1) 8.4 (± 1.4) 
Cerebral Palsy 19 (8.3%) 12 (14.0%) - 10 (8.4%) 
Cystic PVL 18 (8.1%) 6 (6.9%) 7 (8.6%) 6 (4.4%) 
Low 
Developmental 
Score 
16 (8.0%) 9 (10.2%) - 17 (16.4%) 
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Table 2.	Pyrosequencing primers and reaction conditions used in the study 
 
Oligonucleotide Sequence 5’-3’ Product (bp) 
Annealing 
T (°C) Modifications 
EAAT2PyroF-BIO  
EAAT2PyroR  
GGGGCTAAACCTTGCAATC  
GAGTGGCGGGAGCAGAGA  166 60 
5’ Biotin 
None 
EAAT2PyroSeq  GGGTGTGTGCGCGCC  N/A None 
 
Target sequence for pyrosequencing T/GGGGGAGGCGGTGGAGGCCG/TCTG 
Nucleotide dispensation order  CGTGCAGCGTGAGCGTGC  
 
Primer pair EAAT2PyroF-BIO/EAAT2PyroR were used to generate biotinylated PCR 
products flanking SNPs g.-200C>A and g.-181A>C. Primer EAAT2PyroSeq was used for 
pyrosequencing. The target sequence and the order of nucleotide dispensation for the 
pyrosequencing assay are listed. In the dispensation order the nucleotides used as 
negative controls are underlined. In optimal pyrosequencing conditions these nucleotides 
are not incorporated into the target DNA sequence and therefore their addition do not 
generate peaks on the pyrogram (Fig. 1). The nucleotide change in the target sequence for 
pyrosequencing is indicated in bold. 
 
 
Table 3. Summary neurodevelopmental scores and standardised assessment used. 
Results are median (interquartile range - IQR). The standardised neurodevelopmental 
assessment scales used were: Griffith Mental Developmental Scale [30], Bayley Scales of 
infant development 2nd edition (BSID-II) [31] and 3rd edition (BSID-III) [32]. (For details see 
methods section). 
 
Developmental assessment used Median (IQR) 
‘Low 
developmental 
score’ - 10th 
percentile cut-off 
APIP 
   Griffith Mental Developmental Scale 96 (90-105) <82 
Gloucestershire Royal Hospital 
   Griffith Mental Developmental Scale 101 (90-111) <64 
St Michael’s Hospital 
   BSID-II – Mental Developmental Index 94 (70-108) <51 
   BSID-II – Psychomotor Developmental Index 87 (71-100) <53 
   BSID-III – Cognitive Developmental Index 100 (85-110) <76 
   BSID-III  – Language Developmental Index 96 (85-103) <76 
   BSID-III – Psychomotor Developmental Index 96 (89-107) <84 
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Table 4. Distribution of genotypes in the sample cohort. Genotypes were identified by 
pyrosequencing and confirmed by Sanger sequencing (n=51). 
 
Genotype -200C>A -181A>C Number & Proportion 
1 C/C A/A 95 (20.2%) 
2 C/A A/C 261 (55.4%) 
3 A/A C/C 63 (13.4%) 
4 C/A A/A 9 (1.9%) 
5 A/A A/A 2 (0.4%) 
6 C/C A/C 19 (4.0%) 
7 A/A A/C 8 (1.7%) 
8 C/C C/C 1 (0.2%) 
9 C/A C/C 13 (2.8%) 
Allele 
frequency 
C=0.56 
A=0.44 
A=0.53 
C=0.47 
n=471 
 
 
  
	
	
17 
 
Table 5. Intrapartum/perinatal characteristics of the cohort. n - Number of infants with data available. Values are numbers with % or means ± 
standard deviation, as appropriate.  
 
Perinatal 
Measure n -200C>A -181A>C p 
  CC AC AA AA AC CC  
Gestation (week) 466 28.5 (± 2.3) 28.4 (± 2.4) 29.0 (± 2.3) 28.6 (± 2.4) 28.4 (± 2.3) 28.7 (± 2.5) 0.673 
Birth weight (g) 466 1217 (± 402) 1182 (± 437) 1267 (± 466) 1218 (± 403) 1185 (± 438) 1254 (± 462) 0.690 
Male 465 63 (56.8%) 147 (52.7%) 40 (54.8%) 59 (56.2%) 149 (52.7%) 42 (54.6%) 0.525 
Multiple birth 466 28 (24.6%) 68 (24.4%) 22 (30.1%) 24 (22.9%) 75 (26.4%) 19 (24.7%) 0.268 
White ethnicity 333 78 (91.8%) 183 (90.2%) 40 (88.9%) 77 (93.9%) 180 (90.5%) 44 (84.6%) <0.001 
Apgar score 
    1 min 452 6.1 (± 1.9) 6.3 (± 2.2) 6.1 (± 2.1) 6.1 (± 2.0) 6.3 (± 2.1) 6.0 (± 2.2) 0.526 
    5 min 451 8.3 (± 1.5) 8.3 (± 1.7) 8.3 (± 1.6) 8.3 (± 1.5) 8.4 (± 1.6) 8.2 (± 1.7) 0.769 
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Table 6. Univariable associations between genotype and outcome measures. n - Number of infants with data available. Values are numbers 
with %. #Cerebral palsy and low developmental score data were only available from three cohorts (for details see Table 1) 
 
Outcome measure n Homozygote Heterozygote Homozygote p 
-200C>A  CC AC AA  
Cerebral Palsy# 385 9 (9.6%) 23 (9.7%) 3 (5.6%) 0.621 
Cystic PVL 458 7 (6.3%) 21 (7.6%) 3 (4.2%) 0.566 
Low developmental 
score# 349 7 (7.7%) 26 (12.4%) 3 (6.3%) 0.286 
-181A>C  AA AC CC  
Cerebral Palsy# 385 10 (11.4%) 23 (9.5%) 2 (3.9%) 0.263 
Cystic PVL 458 7 (6.7%) 20 (7.3%) 4 (5.2%) 0.817 
Low developmental 
score# 349 11 (12.9%) 22 (10.3%) 3 (5.9%) 0.424 
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Table 7. Multi-level regression analysis for presence of each increasing -200 or -181 A allele and outcomes. (1) Multi-level for neonatal unit of 
care and developmental tool used; (2) Adjusted for gender, birth weight, gestation and Apgar scores at 1 and 5 minutes; (3) Additionally adjusted for 
ethnicity. n - Number of infants with data available. Values are Odds ratio (95% confidence interval). 
 
Outcome Measure Unadjusted (1) Adjusted (2) Adjusted (3) 
 N OR (95% CI) p n OR (95% CI) p n OR (95% CI) p 
-200C>A 
Cerebral Palsy 385 1.70 (0.62-4.66) 0.299 365 1.68 (0.57-4.94) 0.346 314 4.34 (1.12-16.77) 0.033 
Cystic PVL 458 0.88 (0.30-2.58) 0.812 444 0.82 (0.26-2.60) 0.740 317 0.68 (0.13-3.50) 0.641 
Low developmental 
score 349 3.73 (1.29-10.80) 0.015 329 3.23 (1.04-10.02) 0.042 282 2.84 (0.71-11.44) 0.142 
-181A>C 
Cerebral Palsy 385 2.44 (0.87-6.79) 0.089 365 2.72 (0.90-8.22) 0.083 314 6.64 (1.76-25.07) 0.005 
Cystic PVL 458 1.00 (0.32-3.13) 0.812 444 0.99 (0.31-3.10) 0.980 317 0.88 (0.18-4.31) 0.870 
Low developmental 
score 349 4.56 (1.53-13.60) 0.007 329 3.93 (1.23-12.57) 0.013 282 4.15 (1.05-16.38) 0.042 
 
 
  
	
	
20 
Table 8. EAAT2 Genotypes and outcomes.  
 
Genotype Low Developmental Score Cerebral Palsy 
Low Developmental Score 
OR Cerebral Palsy 
A 
alleles 
Genotype 
code 
SNP 
-200bp 
SNP 
-181bp 
Number 
with 
outcomes 
% 
 
Number 
with 
outcomes 
 
% 
Number with 
at least one 
outcome 
 
% 
0 8 C/C C/C 0 - 0 - 0 - 
1 9 C/A C/C 10 1 (10.0%) 10 0   (0.0%) 10 1 (10.0%) 
1 6 C/C A/C 14 0   (0.0%) 16 1   (6.3%) 16 1   (6.3%) 
2 3 A/A C/C 41 2   (4.9%) 46 2   (4.4%) 46 4   (8.7%) 
2 2 C/A A/C 192 21 (10.9%) 218 21   (9.6%) 220 32 (14.6%) 
2 1 C/C A/A 77 7   (9.1%) 78 8 (10.3%) 80 10 (12.5%) 
3 7 A/A A/C 7 1 (14.3%) 7 1 (14.3%) 7 2 (28.6%) 
3 4 C/A A/A 8 4 (50.0%) 9 2 (22.2%) 9 4 (44.4%) 
4 5 A/A A/A 0 - 1 0   (0.0%) 1 0   (0.0%) 
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Fig. 1. 
 
 
 
 
 
 
 
 
Fig. 1. Pyrograms of the EAAT2 promoter SNPs. The position of the SNPs is highlighted in yellow 
boxes, the x-axis of each pyrogram indicates the order of reagent addition (E - enzyme, S - substrate 
and nucleotide A, G, T or C); the y-axis shows the light intensity generated. The numbering of 
pyrograms corresponds to the genotype numbers in Table 1. Due to the high GC content of the 
target sequence and the four C repeats before the SNP at position -181bp, the pyrosequencing was 
carried out on the reverse strand. Thus, note that the sequence is in reverse orientation. 
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Fig. 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Promoter activity of EAAT2. Astrocytes were transiently transfected with sequences 
corresponding to genotype 1 (-200 C/C; -181 A/A) and 3 (-200 A/A; -181 C/C) reporter constructs. 
Firefly and R. reniformis luciferase activities were measured as detailed in the Methods and the 
relative firefly/Renilla luciferase values are shown. Bars represent relative luciferase values from 
three independent experiments with standard deviation. 
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Fig. 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Proposed model of the SNPs impact on EAAT2 gene regulation. (A) EAAT2 promoter 
contains a consensus binding site for transcription factor activating enhancer binding protein 2 (AP-
2), which is an activator of transcription in the developing brain [53]. (B) Nucleotide change from A 
to C at -181bp abolishes this AP-2 consensus sequence and creates a binding site for transcription 
factor GC-binding factor 2 (GCF2) which represses EAAT2 gene expression [19]. (C, D) EAAT2 
promoter is not only controlled by the transcriptional machinery, but is also subject to modulation by 
epigenetic mechanism such as DNA methylation at CpG dinucleotides that inhibits gene expression 
[38, 39, 41, 42]. DNA methylation is reversible and subject to dynamic regulation throughout 
embryogenesis. Nucleotide changes from C to A might interfere with the normal DNA methylation 
process of EAAT2 at both -200bp and -181bp, affecting gene expression. The ability to down 
regulate EAAT2 in the developing brain seems beneficial since infants with three C alleles have 
better outcomes than those with only one. 
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Supplementary material 
 
SNP rs1835740 is located between astrocyte elevated gene 1 (AEG1, also known as MDTH) and 
plasma glutamate carboxypeptidase (PGCP) both involved in glutamate homeostasis [Anttila V, 
Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, et al. (2010) Genome-wide association 
study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 42:869–873]. 
AEG1 downregulates the major glutamate transporter, the excitatory amino-acid transporter-2 
(EAAT2), in the central nervous system (CNS) and PGCP is involved in glutamate synthesis. 
rs1835740 was demonstrated to be a cis-acting regulator of AEG-1, and the risk A allele was 
associated with higher expression levels of AEG1 and the development of migraine and cluster 
headaches, suggesting a link between the rs1835740 variant and impaired regulation of glutamate 
levels in the CNS [Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, et al. 
(2010) Genome-wide association study of migraine implicates a common susceptibility variant on 
8q22.1. Nat Genet 42:869–873]. Our recent work has demonstrated that in infants born at term 
variants of rs1835740 are associated with the need for resuscitation and the length of time the infant 
took to achieve a normal Apgar score [Odd D, Váradi A, Rajatileka S, Molnár E, Luyt K (2016) 
Association between neonatal resuscitation and a single nucleotide polymorphism rs1835740. Acta 
Paediatrica 105:e307-e312]. In infants carrying the A risk allele, the expression of AEG-1 is expected 
to be elevated, which would in turn downregulate EAAT2 resulting in elevated glutamate levels.  
 
Due to the importance of rs1835740 in the regulation of EAAT2, we investigated this SNP in our 
preterm cohort using pyrosequencing as described previously [21] (Supplementary Table 1 and 
Supplementary Fig. 1). The C allele frequency in rs1835740 was 0.77 in our cohort and 0.778 in the 
1,000 Genomes European Reference (p=0.73; European cohort; NCBI SNP Database; 1,000 
Genome Project, Human Build 132/149; Supplementary Tables 2 and 3). There was no evidence of 
deviation from the Hardy-Weinberg equilibrium (p=0.159). rs1835740 did not show significant 
association with CP or with low developmental scores (Supplementary Tables 4-6) and therefore, it 
is likely that it plays no role in the injury of the developing brain.  
 
 
Supplementary Table 1.	Pyrosequencing primers and reaction conditions for rs1835740  
 
Oligonucleotide Sequence 5’-3’ Product 
(bp) 
Annealing  
 T (°C) 
Modifications  
rs1835740PyroF 
rs1835740PyroR-BIO 
CTCATTCGTTTTCTGCCTGTTG 
TCTTGCATATTTGAGCAGACTTTG 
300 60 None 
5’ Biotin 
rs1835740PyroSeq CACAACTTGATTCCAATCT N/A None 
Target sequence for pyrosequencing   GC/TGTATGTAGATT 
Nucleotide dispensation order AGCTCGTAT 
 
Primer pair rs1835740PyroF/rs1835740PyroR-BIO were used to generate biotinylated PCR 
products. Primer rs1835740PyroSeq was used for pyrosequencing. The target sequence and the 
order of nucleotide dispensation for the pyrosequencing assay are listed. In the dispensation order 
the nucleotides used as negative controls are underlined. In optimal pyrosequencing conditions 
these nucleotides are not incorporated into the target DNA sequence and therefore their addition 
do not generate peaks on the pyrogram. The nucleotide change in the target sequence for 
pyrosequencing is indicated in bold. 
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Supplementary Fig. 1. Pyrograms of rs1835740. The position of the SNP is highlighted in yellow 
boxes, the x-axis of each pyrogram indicates the order of reagent addition (E - enzyme, S - substrate 
and nucleotide A, G, T or C); the y-axis shows the light intensity generated. Pyrosequencing was 
carried out on the reverse strand. Thus, note that the sequence is in reverse orientation. 
 
 
 
Supplementary Table 2. Distribution of the rs1835740 alleles in the cohort. 
 
Genotype Alleles Number (Proportion) 
1 C/C 288 (60.0%) 
2 C/T 160 (33.3%) 
3 T/T 32   (6.7%) 
Allele 
frequency 
C=0.77 
T=0.23 
n=480 
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Supplementary Table 3. Intrapartum/perinatal characteristics of the cohort (rs1835740). n - 
Number of infants with data available. Values are numbers with % or means ± standard deviation, 
as appropriate.  
 
Perinatal 
Measure n CC CT TT p 
Gestation (week) 479 28.5 (2.3) 28.3 (2.4) 29.4 (2.4) 0.062 
Birth weight (g) 477 1196 (446) 1148 (396) 1290 (416) 0.055 
Male 478 148 (51.8%) 93 (58.1%) 15 (46.9%) 0.318 
Multiple birth 479 74 (25.8%) 39 (24.4%) 13 (40.6%) 0.155 
White ethnicity 332 178 (87.7%) 98 (94.2%) 25 (84.0%) 0.137 
Apgar score 
    1 min 468 6.3 (2.1) 5.9 (2.3) 6.8 (1.8) 0.052 
    5 min 467 8.3 (1.6) 8.2 (1.8) 8.8 (1.2) 0.324 
 
 
 
Supplementary Table 4. Univariable associations between genotype and outcome measures 
(rs1835740). n - Number of infants with data available. Values are numbers with %. #Cerebral palsy 
and low developmental score data were only available from three cohorts (for details see Table 1) 
 
Outcome measure n Homozygote Heterozygote Homozygote p 
  CC CT TT  
Cerebral Palsy# 386 20   (8.3%) 14 (12.1%) 4 (13.8%) 0.406 
Cystic PVL 468 18   (6.5%) 12   (7.6%) 4 (12.9%) 0.419 
Low developmental 
score# 347 24 (11.0%) 11 (10.2%) 3 (14.3%) 0.858 
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Supplementary Table 5. Multi-level regression analysis for presence of each increasing T allele (rs1835740) and 
outcomes. (1) Multi-level for neonatal unit of care and developmental tool used; (2) Adjusted for gender, birth weight, gestation 
and Apgar scores at 1 and 5 minutes; (3) Additionally adjusted for ethnicity. n - Number of infants with data available. Values 
are Odds ratio (95% confidence interval). 
 
Outcome Measure Unadjusted (1) Adjusted (2) Adjusted (3) 
 N OR (95% CI) p n OR (95% CI) p n OR (95% CI) p 
rs1835740 T>C 
Cerebral Palsy 386 1.39 (0.85-2.27) 0.190 372 1.41 (0.84- 2.36) 0.192 313 1.66 (0.96-2.85) 0.069 
Cystic PVL 468 1.36 (0.80-2.30) 0.258 457 1.39 (0.81-2.40) 0.232 314 1.33 (0.70-2.54) 0.384 
Low developmental 
score 347 1.05 (0.61-1.83) 0.850 333 1.03 (0.57-1.88) 0.916 279 1.23 (0.63-2.40) 0.539 
 
 
 
Supplementary Table 6. Genotypes and outcomes (rs1835740).  
 
Genotype Low Developmental Score Cerebral Palsy Low Developmental Score OR Cerebral Palsy 
T 
alleles 
Genotype 
code SNP 
Number with 
outcomes % 
Number with 
outcomes % 
Number with 
at least one 
outcome 
% 
0 1 C/C 218 24 (11.0%) 241 20   (8.3%) 242 34 (14.1%) 
1 2 C/T 108 11 (10.2%) 116 14 (12.1%) 118 19 (16.1%) 
2 3 T/T 21 3 (14.3%) 29 4   (9.8%) 29 5 (17.2%) 
 
